Baricitinib: Difference between revisions
From IDWiki
(Created page with "==Background== * Oral JAK inhibitor * Indications include COVID-19 ==Dosing== * 4 mg p.o. daily for 14 days, or until hospital discharge ===Renal Dosing=== * eGFR 30-60...") |
No edit summary |
||
| Line 9: | Line 9: | ||
* eGFR 30-60 mL/min: 2 mg p.o. daily |
* eGFR 30-60 mL/min: 2 mg p.o. daily |
||
* eGFR 15-30 mL/min: 1 mg p.o. daily |
* eGFR 15-30 mL/min: 1 mg p.o. daily |
||
== Safety == |
|||
=== Contraindications === |
|||
* Contraindications and relative contraindications include hypersensitivity, co-existing infection, immunosuppression, increase liver enzymes. |
|||
[[Category:Medications]] |
[[Category:Medications]] |
||
Latest revision as of 23:01, 13 January 2022
Background
- Oral JAK inhibitor
- Indications include COVID-19
Dosing
- 4 mg p.o. daily for 14 days, or until hospital discharge
Renal Dosing
- eGFR 30-60 mL/min: 2 mg p.o. daily
- eGFR 15-30 mL/min: 1 mg p.o. daily
Safety
Contraindications
- Contraindications and relative contraindications include hypersensitivity, co-existing infection, immunosuppression, increase liver enzymes.
